Literature DB >> 29312767

Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.

Paul G Werthmann1, Gerhard Saltzwedel2, Gunver S Kienle1,3.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare cancer with a dismal prognosis. Viscum album extracts (VAE) have strong immune stimulatory properties, cytotoxic effects, can downregulate cancer genes and inhibit angiogenesis. VAE are often used as an adjunct treatment in cancer patients but have rarely been investigated in MPM. Helleborus niger extracts (HNE) have been used in anticancer therapy since antiquity, and also show tumor specific cytotoxic effects. We present a case of a 64-year old woman with epithelioid MPM of the right chest with node involvement (T2N1M0, stage III). Deciding against the recommended radio-chemotherapy, surgery and pleurodesis, she opted for an integrative treatment approach and was treated with VAE and HNE. After 6 weeks' treatment, the pleural and nodal MPM manifestations were reduced by about 15%. Subsequent tumor growth was slow, and the patient remained in good health, enabling her to remain physically active until shortly before her death 56 months after the initial diagnosis. This is a rare case of an MPM patient not receiving any standard anticancer treatment; it still shows an extraordinary long survival and good performance status. We presume that VAE and HNE might had an impact on this clinically relevant outcome and therefore should be further investigated in MPM.

Entities:  

Keywords:  GM-CSF; Helleborus niger extract (HNE); Malignant pleural mesothelioma (MPM); Viscum album extract (VAE); dendritic cells

Year:  2017        PMID: 29312767      PMCID: PMC5757010          DOI: 10.21037/jtd.2017.11.56

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  23 in total

1.  Malignant pleural mesothelioma: a population-based study of survival.

Authors:  Michael T Milano; Hong Zhang
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

Review 2.  Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies.

Authors:  Gunver S Kienle; Helmut Kiene
Journal:  Integr Cancer Ther       Date:  2010-05-18       Impact factor: 3.279

3.  Apoptosis-inducing activity of Helleborus niger in ALL and AML.

Authors:  Patrick Jesse; Gritt Mottke; Jürgen Eberle; Georg Seifert; Günter Henze; Aram Prokop
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

4.  Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.

Authors:  W Tröger; D Galun; M Reif; A Schumann; N Stanković; M Milićević
Journal:  Eur J Cancer       Date:  2013-07-24       Impact factor: 9.162

5.  Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts--a case report.

Authors:  Paul Georg Werthmann; Gregor Sträter; Hedda Friesland; Gunver Sophia Kienle
Journal:  Phytomedicine       Date:  2013-02-15       Impact factor: 5.340

6.  Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.

Authors:  Masaki Anraku; Kristopher S Cunningham; Zhihong Yun; Ming-Sound Tsao; Li Zhang; Shaf Keshavjee; Michael R Johnston; Marc de Perrot
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

7.  Malignant pleural mesothelioma: an epidemiological perspective.

Authors:  Benjamin M Robinson
Journal:  Ann Cardiothorac Surg       Date:  2012-11

8.  Anthroposophic medicine: an integrative medical system originating in europe.

Authors:  Gunver S Kienle; Hans-Ulrich Albonico; Erik Baars; Harald J Hamre; Peter Zimmermann; Helmut Kiene
Journal:  Glob Adv Health Med       Date:  2013-11

9.  Individualized Integrative Cancer Care in Anthroposophic Medicine: A Qualitative Study of the Concepts and Procedures of Expert Doctors.

Authors:  Gunver S Kienle; Milena Mussler; Dieter Fuchs; Helmut Kiene
Journal:  Integr Cancer Ther       Date:  2016-05-04       Impact factor: 3.279

10.  Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

Authors:  M Mabed; L El-Helw; S Shamaa
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  15 in total

1.  Application of the CARE guideline as reporting standard in the Journal of Gastrointestinal Oncology.

Authors: 
Journal:  J Gastrointest Oncol       Date:  2020-08

2.  Application of the CARE guideline as reporting standard in the Journal of Spine Surgery.

Authors: 
Journal:  J Spine Surg       Date:  2019-12

3.  Application of the CARE guideline as reporting standard in the Translational Andrology and Urology.

Authors: 
Journal:  Transl Androl Urol       Date:  2019-12

4.  Application of the CARE guideline as reporting standard in the Gland Surgery.

Authors: 
Journal:  Gland Surg       Date:  2019-12

5.  Application of the CARE guideline as reporting standard in the Translational Lung Cancer Research.

Authors: 
Journal:  Transl Lung Cancer Res       Date:  2019-12

6.  Application of the CARE guideline as reporting standard in the Stem Cell Investigation.

Authors: 
Journal:  Stem Cell Investig       Date:  2019-12-05

7.  Application of the CARE guideline as reporting standard in the AME Case Reports.

Authors: 
Journal:  AME Case Rep       Date:  2019-12-12

8.  Application of the CARE guideline as reporting standard in the Annals of Translational Medicine.

Authors: 
Journal:  Ann Transl Med       Date:  2019-12

9.  Application of the CARE guideline as reporting standard in the Translational Gastroenterology and Hepatology.

Authors: 
Journal:  Transl Gastroenterol Hepatol       Date:  2019-11-26

10.  Application of the CARE guideline as reporting standard in the mHealth.

Authors: 
Journal:  Mhealth       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.